IDEAYA Biosciences, Inc. (IDYA)
| Market Cap | 489.82M |
| Revenue (ttm) | 8.97M |
| Net Income (ttm) | -40.14M |
| Shares Out | 28.40M |
| EPS (ttm) | -1.78 |
| PE Ratio | n/a |
| Forward PE | 4.65 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $16.85 |
| Previous Close | $16.34 |
| Change ($) | 0.51 |
| Change (%) | 3.12% |
| Day's Open | 16.40 |
| Day's Range | 16.29 - 17.49 |
| Day's Volume | 1,476,717 |
| 52-Week Range | 3.03 - 18.57 |
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of ...
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of t...
SOUTH SAN FRANCISCO, Calif., Jan. 4, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of t...
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of...
IDEAYA Biosciences (IDYA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of...
SOUTH SAN FRANCISCO, Calif., Nov. 2, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of t...
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of...
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development o...
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of -126.34% and -100.00%, respectively, for the quarter ended June 2020.
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.
IDEAYA Biosciences (IDYA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SOUTH SAN FRANCISCO, Calif., Aug. 4, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., July 16, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., July 14, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of...
SOUTH SAN FRANCISCO, Calif., July 9, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of t...
SOUTH SAN FRANCISCO, Calif., June 30, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of ...
A high-profile partnership and a promising pipeline of oncology-focused treatments suggest favorable reward-versus-risk in IDYA stock. The post Target Breakthrough Science and Medicine with Id...
Here's what pushed up shares of the highest-flying healthcare stocks.
The development-stage drug developer is selling common stock to raise cash. It's a wise move.
SOUTH SAN FRANCISCO, Calif., June 17, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of 6,666,667 shares of its com...
SOUTH SAN FRANCISCO, Calif., June 16, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $60 million of shares of its common st...
IDEAYA Biosciences (NASDAQ: IDYA) shares are trading higher on Tuesday, after the company, along with GSK, announced a partnership in Synthetic Lethality.
SOUTH SAN FRANCISCO, Calif. and LONDON, June 16, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) and GlaxoSmithKline plc (GSK) announce a strategic partnership in Synthetic Lethal...
SOUTH SAN FRANCISCO, Calif., June 11, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development o...
IDEAYA (IDYA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
SOUTH SAN FRANCISCO, Calif., June 8, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of ...
SOUTH SAN FRANCISCO, Calif., May 19, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of t...
SOUTH SAN FRANCISCO, Calif., May 15, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of...
About IDYA
IDEAYA Biosciences, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase 1/2 clinical trial for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A for solid tumors with MTAP deletions; Pol-theta in tumors with homologous recombination de... [Read more...]
| Industry Biotechnology | IPO Date May 23, 2019 |
| CEO Yujiro Hata | Employees 58 |
| Stock Exchange NASDAQ | Ticker Symbol IDYA |
Analyst Forecasts
According to 9 analysts, the average rating for IDYA stock is "Strong Buy." The 12-month stock price forecast is 24.56, which is an increase of 45.76% from the latest price.